Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Precision Biosciences Inc (NQ: DTIL )

13.15 +0.10 (+0.77%)
Streaming Delayed Price Updated: 9:44 AM EDT, May 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Precision Biosciences Inc

< Previous 1 2 3 4 5 Next >
Precision BioSciences Recaps 2022 Accomplishments and Outlines 2023 Corporate Priorities and Planned Portfolio Milestones
From Precision BioSciences
Via Business Wire
Precision BioSciences Receives Favorable Type C Feedback from the FDA on the Company’s Chemistry, Manufacturing, and Controls (CMC) Strategies for Late-Stage Development of Azercabtagene Zapreleucel, its Lead Allogeneic CAR T Clinical Candidate
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Presents Analysis of Azer-Cel, Allogeneic CAR T Product Attributes Related to In Vivo Pharmacokinetics, Pharmacodynamics, and Clinical Outcomes at 2022 American Society of Hematology Annual Meeting
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Announces Change to its Board of Directors
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Reports Third Quarter 2022 Financial Results and Provides Business Update
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Announces Data Presentation on Effective Cell Dose and Functional Attributes of CD19 Allogeneic CAR T, Azer-Cel, at the Upcoming 2022 American Society of Hematology (ASH) Annual Meeting
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences to Report Third Quarter 2022 Financial Results on November 8, 2022
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Announces Grant of Inducement Award Pursuant to Nasdaq Listing Rule 5635(c)(4)
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences to Present at the European Society of Gene & Cell Therapy (ESGCT) 29th Congress
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences to Participate in Upcoming Jefferies Cell & Genetic Medicine Summit
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences to Participate in Upcoming H.C. Wainwright 24th Annual Global Investment Conference
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Announces Senior Leadership Organizational Changes
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Reports Second Quarter 2022 Financial Results and Provides Business Update
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences to Report Second Quarter 2022 Financial Results on August 8, 2022
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Precision BioSciences, Inc.
Via Business Wire
Global Pancreatic Cancer Therapeutics & Diagnostics Market Expected To Reach $5.6 Billion By 2027
Palm Beach, FL – June 28, 2022 – FinancialNewsMedia.com News Commentary – Pancreatic cancer therapeutics and diagnostics involve medical procedures used to diagnose pancreatic cancer and subsequent... 
Via FinancialNewsMedia
Precision BioSciences Announces Closing of Underwritten Offering of Common Stock
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Announces $50 Million Offering of Common Stock
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Announces In Vivo Gene Editing Collaboration with Novartis to Develop Potentially Curative Treatment for Disorders Including Sickle Cell Disease
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Provides Update on Allogeneic CAR T Programs and Path Forward with Its Lead PBCAR0191 Candidate for CAR T Relapsed Patient Population
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences to Provide an Update on its Ongoing Allogeneic CAR T Programs via Hosted Virtual Webcast and Conference Call on Wednesday, June 8, 2022
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences to Participate in Upcoming Jefferies Healthcare Conference
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Appoints Melinda Brown to Board of Directors
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Appoints Juli Blanche as Chief People Officer
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Announces Publication in Molecular Therapy of ARCUS® In Vivo Gene Editing as a Promising Therapeutic Approach to Cure Chronic Hepatitis B Infection
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Announces Preclinical Data Showcasing Premier In Vivo Gene Editing Capabilities at American Society of Gene & Cell Therapy Annual Meeting
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Reports First Quarter 2022 Financial Results and Provides Business Update
From Precision BioSciences, Inc.
Via Business Wire
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.